Solomon B.J.Besse B.Bauer T.M.Felip E.Soo R.A.Camidge D.R.Chiari R.Bearz A.CHIA-CHI LINGadgeel S.M.Riely G.J.Tan E.H.Seto T.James L.P.Clancy J.S.Abbattista A.Martini J.-F.Chen J.Peltz G.Thurm H.Ignatius Ou S.-H.Shaw A.T.2022-09-152022-09-1520181470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057172350&doi=10.1016%2fS1470-2045%2818%2930649-1&partnerID=40&md5=4f1e248ef686628c67ef5c996351e913https://scholars.lib.ntu.edu.tw/handle/123456789/620262[SDGs]SDG3Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyjournal article10.1016/S1470-2045(18)30649-1304133782-s2.0-85057172350